Guinea Receives Ebola Vaccination

The Russian Health Ministry acting together with Aluminium (RUSAL), one of the world’s largest aluminium producers, has tested an Ebola vaccine in the Republic of Guinea.

Two thousand (2,000) people received the GamEvac-Combi vaccines during the testing programme conducted at the Scientific Diagnostic Centre for Epidemiology and Microbiology (SDCEM) in Guinea.

The centre, an initiative of Russian business tycoon, Oleg Deripaska, was built by RUSAL during the height of the Ebola epidemic in 2015.

GamEvac-Combi vaccine was created in the Gamalei Federal Research Centre for Epidemiology and Microbiology of the Ministry of Health of the Russian Federation.

The vaccine is currently in the final round of testing.

“As part of the testing programme, the health of the vaccinated participants and the development of the immunity are monitored for one year.

“At the end of this period of monitoring, the vaccine will receive international certification making it available for use by the World Health Organisation and other organizations for the purpose of preventing the spread of the disease,” according to media release.

Russian President, Vladimir Putin, instructed the development of the vaccine following a request from his Guinean counterpart, President Alpha Condé at the end of 2014.

The vaccine was revealed during the World Health Assembly in 2016, which was attended by the former WHO Director-General, Margaret Chen.

Alongside, the development of the vaccine, RUSAL, as part of the public-private partnership supported by Oleg Deripaska, opened a research centre, an isolation ward and a hospital in Guinea.

RUSAL’s commitment to fighting the epidemic was acknowledged by the Russian Minister of Foreign Affairs, Sergey Lavrov, who thanked RUSAL’s shareholder, Oleg Deripaska, for his contribution to the international effort against Ebola.

The strong relationship that RUSAL has established with the Republic of Guinea is something that Oleg Deripaska often speaks about.

He recently highlighted RUSAL’s commitment to helping the population of the country hit by the virus; and said “when the outbreak of the fever came, we made every effort to help”.

“Currently the vaccine is administered to the Russian medics and other specialists going to the regions where there is a high risk of Ebola contagion”, said Veronika Skvortsova, the Health Minister.

“During the Ebola outbreak, the centre has shown the best results in terms of the number of Guinean persons wholly recovered: 62.5% of the SDCEM patients with a confirmed Ebola fever diagnosis have been successfully treated”.

The vaccine was developed using a biotechnology method without using the pathogenic Ebola virus. The base of the vaccine is the genetic material of an adenovirus and vesicular canker virus, safe for humans, modified with a gene containing the information about the structure of the GP protein of the Ebola virus.

Pre-clinical and clinical studies have proven the safety of the vaccine and have shown that it stimulates the immune system more efficiently than foreign vaccines.

Another important advantage of the vaccine is its more favourable transportation and storage conditions: GamEvac-Combi can be transported and stored at the temperature above -16?C.

RUSAL invested more than US$10 million in the construction of the SDCEM.

Currently, SDCEM is the leading centre in the field of investigating and preventing infectious diseases in Guinea. It also serves as the training facility for the national epidemiologists.

RUSAL has been active in Guinea since 2001 being one of the largest foreign investors in the country – owns Kindia Bauxite Company (KBC) as well as the bauxite-alumina facility Friguia.

Source: GNA